Wednesday, November 11, 2026
Via News Knowledge File

Morgan Stanley & Co. LLC

organization80% conf.·synced Nov 11, 2026

Financial advisor to Avadel in the proposed transaction

60
sourced metrics
1112
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
228.55USD
Nov 10, 2026reference only
Stock Return Ytd
3.1%
Nov 10, 2026reference only
Price 52 Week Low
154.37USD
Nov 10, 2026reference only
Market Cap
294575413728USD
Nov 10, 2026reference only
Stock Price
187.56USD
Nov 10, 2026reference only
Shares Outstanding
1570566292.0shares
Jul 31, 2026reference only
Eps
3.46USD_per_share
Jun 30, 2026reference only
Cash
160135000000.0USD
Jun 30, 2026reference only
Total Liabilities
1557617000000.0USD
Jun 30, 2026reference only
Net Income
5581000000.0USD
Jun 30, 2026reference only
Stockholders Equity
116329000000.0USD
Jun 30, 2026reference only
Total Assets
1675057000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
-7098000000.0USD
Mar 31, 2026reference only

Stated objectives

Morgan Stanley increasing focus on less capital market-dependent operations to aid growth and enhance capital distribution activities

source
stated

Achieve ROTCE in the low to mid-20s over time through synergies and capital deployment

source
target: low-to-mid-20s stated

New recommended portfolio allocation: 60% stocks, 20% fixed income, 20% gold

source
target: 60/20/20 stated

Path to over $10 trillion in client assets

source
target: 10 stated

Sustained 20%+ ROTCE through market cycles

source
target: 20 stated

Ability to generate 17.5% ROTCE in challenging environment with earnings below $8

source
target: 17.5 stated

Scale AI tools throughout the enterprise and client base

source
stated

Institutional trading wallet growth of 5-10% per annum

source
target: 5-10 stated

Recommend investors shift from 60/40 stocks/bonds to 60/20/20 stocks/fixed income/gold allocation

source
target: 60% stocks, 20% fixed income, 20% gold stated

S&P 500 to reach 7,500 by year-end 2026

source
target: 7500 by 2026-12-31 00:00:00stated

Relationship graph · 1112 connections

Covered by
490
Employs
274
rates
78
underwrites
46
Competes with
44
subsidiary of
34
Developed by
19
regulates
14

Where sources disagree

We surface conflicts between sources rather than hiding them.

value conflictunresolved

Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.

value conflictunresolved

The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.

value conflictunresolved

Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com